{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:36:23Z","timestamp":1789403783488,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ebiom.2026.106230","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:42:54Z","timestamp":1774374174000},"page":"106230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development and preclinical evaluation of KDTV001, an adenovirus 5-vectored trivalent HPV therapeutic vaccine targeting HPV16\/18\/52"],"prefix":"10.1016","volume":"126","author":[{"given":"Yilin","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3929-2440","authenticated-orcid":false,"given":"Xiaojiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3238-6757","authenticated-orcid":false,"given":"Rui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-4185","authenticated-orcid":false,"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ebiom.2026.106230_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"10.1016\/j.ebiom.2026.106230_bib2","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical cancer immunotherapy: facts and hopes","volume":"27","author":"Ferrall","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106230_bib3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41571-024-00904-z","article-title":"Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination","volume":"21","author":"Malag\u00f3n","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ebiom.2026.106230_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.909223","article-title":"Prophylactic and therapeutic HPV vaccines: current scenario and perspectives","volume":"12","author":"Mo","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106230_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12929-016-0293-9","article-title":"Perspectives for therapeutic HPV vaccine development","volume":"23","author":"Yang","year":"2016","journal-title":"J Biomed Sci"},{"issue":"10008","key":"10.1016\/j.ebiom.2026.106230_bib6","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: a randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106230_bib7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/ajcp\/aqab181","article-title":"Nationwide prevalence and genotype distribution of high-risk human papillomavirus infection in China","volume":"157","author":"Zeng","year":"2022","journal-title":"Am J Clin Pathol"},{"issue":"16","key":"10.1016\/j.ebiom.2026.106230_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70148","article-title":"Prevalence and genotype distribution of HPV combined with cervical pathological results in women from Sichuan, China: a cross-sectional study based on post-vaccination period 2019 to 2023","volume":"13","author":"Mo","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106230_bib9","doi-asserted-by":"crossref","first-page":"e2176009","DOI":"10.1080\/22221751.2023.2176009","article-title":"Cervical HPV infection in Guangzhou, China: an epidemiological study of 198,111 women from 2015 to 2021","volume":"12","author":"Yang","year":"2023","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106230_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12985-024-02317-x","article-title":"Prevalence and genotype distribution of HPV infections among women in Chengdu,China","volume":"21","author":"Zhang","year":"2024","journal-title":"Virol J"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106230_bib11","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3","volume":"26","author":"Choi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106230_bib12","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1158\/1078-0432.CCR-24-1662","article-title":"Vvax001, a therapeutic vaccine, for patients with HPV16-positive high-grade cervical intraepithelial neoplasia: a phase II trial","volume":"31","author":"Eerkens","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ebiom.2026.106230_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","article-title":"Human papillomavirus vaccine against cervical cancer: opportunity and challenge","volume":"471","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106230_bib14","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","article-title":"Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial","volume":"21","author":"Wu","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106230_bib15","article-title":"Adenoviral vector-based vaccine platform for COVID-19: current status","volume":"11","author":"Chavda","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106230_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/v16030377","article-title":"Advances of recombinant adenoviral vectors in preclinical and clinical applications","volume":"16","author":"Scarsella","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ebiom.2026.106230_bib17","article-title":"Adenoviral vectors as vaccines for emerging Avian influenza viruses","volume":"11","author":"Kerstetter","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106230_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.752","article-title":"Epitope identification for p53R273C mutant","volume":"11","author":"Zhang","year":"2023","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106230_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106230_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","article-title":"Scrublet: computational identification of cell doublets in single-cell transcriptomic data","volume":"8","author":"Wolock","year":"2019","journal-title":"Cell Syst"},{"key":"10.1016\/j.ebiom.2026.106230_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12688\/f1000research.22139.1","article-title":"scRepertoire: an R-based toolkit for single-cell immune receptor analysis","volume":"9","author":"Borcherding","year":"2020","journal-title":"F1000Res"},{"issue":"31","key":"10.1016\/j.ebiom.2026.106230_bib22","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.vaccine.2017.05.081","article-title":"Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model","volume":"35","author":"Ma","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2026.106230_bib23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/978-1-0716-0795-4_32","article-title":"A method to evaluate In Vivo CD8(+) T cell cytotoxicity in a murine model","volume":"2183","author":"Stark","year":"2021","journal-title":"Methods Mol Biol"},{"issue":"686","key":"10.1016\/j.ebiom.2026.106230_bib24","doi-asserted-by":"crossref","first-page":"eabn3464","DOI":"10.1126\/scitranslmed.abn3464","article-title":"Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice","volume":"15","author":"Ramos Da Silva","year":"2023","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106230_bib25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/cgt.2012.55","article-title":"A non-oncogenic HPV 16 E6\/E7 vaccine enhances treatment of HPV expressing tumors","volume":"19","author":"Wieking","year":"2012","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106230_bib26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.vaccine.2008.10.078","article-title":"Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6\/E7 fusion antigen","volume":"27","author":"Yan","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2026.106230_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jviromet.2014.05.013","article-title":"DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice","volume":"206","author":"Bahrami","year":"2014","journal-title":"J Virol Methods"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106230_bib28","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1093\/emboj\/18.9.2449","article-title":"The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth","volume":"18","author":"Brehm","year":"1999","journal-title":"Embo j"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106230_bib29","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cell.2020.11.041","article-title":"Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma","volume":"184","author":"Sun","year":"2021","journal-title":"Cell"},{"issue":"29","key":"10.1016\/j.ebiom.2026.106230_bib30","doi-asserted-by":"crossref","first-page":"e2203040","DOI":"10.1002\/advs.202203040","article-title":"Single-nucleus RNA sequencing and spatial transcriptomics reveal the immunological microenvironment of cervical squamous cell carcinoma","volume":"9","author":"Ou","year":"2022","journal-title":"Adv Sci (Weinh)"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106230_bib31","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/cvr\/cvac161","article-title":"Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis","volume":"119","author":"Zernecke","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"17","key":"10.1016\/j.ebiom.2026.106230_bib32","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1016\/j.cell.2024.06.038","article-title":"Pan-cancer single-cell dissection reveals phenotypically distinct B cell subtypes","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106230_bib33","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.ccell.2024.09.011","article-title":"A pan-cancer single-cell RNA-seq atlas of intratumoral B cells","volume":"42","author":"Fitzsimons","year":"2024","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106230_bib34","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ccell.2023.06.005","article-title":"Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"issue":"6574","key":"10.1016\/j.ebiom.2026.106230_bib35","doi-asserted-by":"crossref","first-page":"abe6474","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106230_bib36","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202317723","article-title":"Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine","volume":"15","author":"Douguet","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106230_bib37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2568","article-title":"Sensing and alarm function of resident memory CD8+ T cells","volume":"14","author":"Schenkel","year":"2013","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106230_bib38","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106230_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","article-title":"Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial","volume":"10","author":"Li","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106230_bib40","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.4161\/hv.34378","article-title":"ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen","volume":"10","author":"Cory","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106230_bib41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jinf.2021.02.017","article-title":"Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: a nationwide population-based study","volume":"82","author":"Bao","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.ebiom.2026.106230_bib42","article-title":"Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation","volume":"8","author":"Kombe Kombe","year":"2020","journal-title":"Front Public Health"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106230_bib43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2144\/btn-2022-0051","article-title":"Adenovirus vector system: construction, history and therapeutic applications","volume":"73","author":"Syyam","year":"2022","journal-title":"Biotechniques"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106230_bib44","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.32470","article-title":"A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice","volume":"76","author":"Donnison","year":"2022","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106230_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009644","article-title":"Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8(+) T cell control of tumor challenge in mice","volume":"12","author":"Dagotto","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"13","key":"10.1016\/j.ebiom.2026.106230_bib46","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","article-title":"New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses","volume":"9","author":"Fallaux","year":"1998","journal-title":"Hum Gene Ther"},{"issue":"7090","key":"10.1016\/j.ebiom.2026.106230_bib47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106230_bib48","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1089\/vim.2023.0023","article-title":"Characterization of pre-existing neutralizing antibody to human adenovirus types 5 and 49 and simian type 23 in Chinese population","volume":"36","author":"Zou","year":"2023","journal-title":"Viral Immunol"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106230_bib49","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1007\/s00705-021-05234-4","article-title":"Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice","volume":"166","author":"Zhao","year":"2021","journal-title":"Arch Virol"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106230_bib50","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.4049\/jimmunol.1501926","article-title":"A recombinant chimeric Ad5\/3 vector expressing a multistage plasmodium antigen induces protective immunity in mice using heterologous prime-boost immunization regimens","volume":"197","author":"Cabrera-Mora","year":"2016","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.ebiom.2026.106230_bib51","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/1078-0432.CCR-23-3940","article-title":"Phase I trial of viral vector-based personalized vaccination elicits robust neoantigen-specific antitumor T-Cell responses","volume":"30","author":"D'alise","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106230_bib52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41417-025-00884-x","article-title":"Chimeric Ad5\/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency","volume":"32","author":"Dai","year":"2025","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2026.106230_bib53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41571-024-00977-w","article-title":"Treatment advances across the cervical cancer spectrum","volume":"22","author":"Francoeur","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106230_bib54","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.ymthe.2024.04.036","article-title":"Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies","volume":"32","author":"Wang","year":"2024","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106230_bib55","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2017.52","article-title":"A STING-activating nanovaccine for cancer immunotherapy","volume":"12","author":"Luo","year":"2017","journal-title":"Nat Nanotechnol"},{"issue":"6719","key":"10.1016\/j.ebiom.2026.106230_bib56","doi-asserted-by":"crossref","first-page":"eadn9083","DOI":"10.1126\/science.adn9083","article-title":"In vivo dendritic cell reprogramming for cancer immunotherapy","volume":"386","author":"Ascic","year":"2024","journal-title":"Science"},{"issue":"91","key":"10.1016\/j.ebiom.2026.106230_bib57","doi-asserted-by":"crossref","first-page":"eadi9517","DOI":"10.1126\/sciimmunol.adi9517","article-title":"CD4(+) T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses","volume":"9","author":"Bawden","year":"2024","journal-title":"Sci Immunol"},{"issue":"7780","key":"10.1016\/j.ebiom.2026.106230_bib58","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106230_bib59","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"10460","key":"10.1016\/j.ebiom.2026.106230_bib60","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(24)01808-7","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106230_bib61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00281-023-00986-4","article-title":"Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16","volume":"45","author":"Melief","year":"2023","journal-title":"Semin Immunopathol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642600112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239642600112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:59:42Z","timestamp":1783972782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239642600112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":61,"alternative-id":["S235239642600112X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106230","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and preclinical evaluation of KDTV001, an adenovirus 5-vectored trivalent HPV therapeutic vaccine targeting HPV16\/18\/52","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106230","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106230"}}